Skip to main content
NCBI home page
Medicine logoLink to Medicine
. 2021 Aug 13;100(32):e26849. doi: 10.1097/MD.0000000000026849

Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer

A systematic review and meta-analysis

Luting Liu 1,∗, Wanchun Xiong 1
Editor: Supreet Agarwal1
PMCID: PMC8360434  PMID: 34397893

Abstract

This study aimed to investigate the effect of molecular targeted agents (MTAs) in chemo on platinum-resistant recurrent ovarian cancer (ROC). We performed this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements. Randomized controlled trials reporting data about platinum-resistant ovarian cancer treated by MTAs were included. The endpoints for the present study included overall survival and progression-free survival. We analyzed 9 randomized controlled trials including 3631 patients with ROC. The pooled analysis indicated that a combination of MTAs with chemo could markedly increase objective response rate in those patients (P = .012). Nevertheless, the survival rate of those patients was not markedly changed (P = .19). Besides, the combination of MTAs with chemo dramatically aggravated the occurrence of adverse events (P < .05). Moreover, it resulted in the termination of treatment (P = .044) in those patients, but it had no effect on fatal adverse events (P = .16). Our results indicated that the combination of MTAs with chemo notably improved objective response rate in patients with platinum-resistant ROC, but its benefit did not translate into survival benefits.

Keywords: chemotherapy, molecular targeted agents, platinum-resistant, recurrent ovarian cancer

1. Introduction

Ovarian carcinoma (OC) is a common lethal gynecological cancer, and it has been reported that more than 280,000 new cases and 180,000 deaths are being identified annually.[1] Symptoms of ovarian are usually developed into late-stage due to its biology. As a result, over 70% have already had advanced-stage disease among patients with OC when they were diagnosed.[2,3] The current treatment methods include surgical resection and chemotherapy, which contain carboplatin and paclitaxel.[4,5] Although most patients have fewer symptoms after treatment, most of them eventually suffer from relapse and drug resistance.[6,7] For patients with platinum-resistant recurrent ovarian cancer (ROC), the treatment effects of the current schemes are similar. Unfortunately, there is no standard or effective chemotherapy for platinum-resistant ROC.[8–11] Therefore, novel effect treatment options are needed for ROC patients.

In the past few decades, the emerging understandings of the underlying molecular mechanisms of carcinogenesis led to the identification of novel drugs for the treatment of OC. These drugs treat OC by acting on key factors or signaling pathways related to tumor cell proliferation and invasion. Several molecularly targeted agents (MTAs) have been developed. There are memorable therapeutic effects of them on patients with OC,[12–16] which results in the application of bevacizumab and poly(ADP)-ribose polymerase inhibitors for treating advanced OC.[17–19] However, there are still doubts about the efficacy of the new MTAs in treating platinum-resistant ROC remains contentious. Therefore, in the present study, randomized controlled studies relating to ROC were included to assess the effect of combined use of MTAs with chemotherapy for platinum-resistant ROC patients by meta-analysis.

2. Materials and methods

2.1. Study design

We performed this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements.[20] Ethical approval was avoided in this study.

2.2. Definition of the study results

We included the studies in which MTAs were used as an experimental group while the others were the control group. The endpoints of treatment in this study included: (1) overall survival (OS), which was the period between enrolled group and death, examining subjects who were survival; (2) progression-free survival (PFS), which was the period between enrolled group and development recorded for the first time; and (3) objective response rate (ORR), including partial or whole response rate and stabilization rate.

2.3. Search strategy

Electronic databases were searched, including PubMed, Embase, and Cochrane Library to select related studies published before April, 2019, in which MTAs were the second treatment for ROC. The key terms to search studies included: (“ovarian carcinoma” or “ovarian cancer,” or “gynecological cancer,” or “gynecological carcinoma” or “ovarian epithelial cancer”) and (“recurrent” or “refractory”) and (“molecularly targeted agents,” or “sunitinib,” or “vandetanib,” “pazopanib,” or “trebananib,” or “trabectedin,” or “axitinib,” or “aflibercept,” or “seribantumab”). The studies we searched only included randomized controlled trials (RCTs) in humans. There was no language restriction.

2.4. Inclusion criteria

Inclusion criteria were: (1) pathological confirm of platinum-resistant ROC patients; (2) ROC patients received systematic or combination chemotherapy with MTAs randomly; and (3) results including treatment effect, survival, or toxicity, were reported in included trials.

2.5. Data extraction

Two investigators (XWC and YCR) searched and extracted the data from the trials independently. There was no difference between title, summary, and the trial to be studied. If the 2 reviewers had different suggestions, the third reviewer (LLT) will make a final decision. We summed up those data from each trial enrolled in this study, including the authors, publishing time, follow-up period, sample size, median age, chemotherapy regimens, and survival outcomes.

2.6. Statistical analysis

The critical outcome included OS, and the subordinate endpoint included PFS, ORR, and toxicities. The fixed-effects model or random-effects model was carried out to analyze the patients treated with combination MTAs with chemotherapy with hazard ratios (HRs) and 95% confidence interval (CI) when minimal or significant heterogeneity existed in the variables, respectively. There were statistical significances in heterogeneity when P < .1 (X2 test) and >50% (I2 test). Comprehensive Meta-Analysis program (Biostat, Englewood, NJ) was used to perform Forest plots to sum up the included studies. The publication bias was assessed using Egger regression asymmetry, the Begg rank correlation, and the funnel plots.

3. Results and discussion

3.1. Search outcomes

There were 606 clinical trials including PubMed 408, ASCO 128, ESMO 70, relevant to MTAs as methods to treating advanced ROC. There were 9 prospective RCTs in this study (Fig. 1), with 2388 patients with platinum-resistant ROC.[21–29] Sample size included in every included study was 91 (range: 22–703 patients). Jadad scale was carried out to evaluate the quality of each trial, and the results showed 4 trials with 5 scores and 5 trials with 3 scores.

Figure 1.

Figure 1

Open in a new tab

PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

3.2. Efficacy of MTAs in platinum-resistant ROC

Nine included trials reported the PFS data. The pooled analysis showed that MTAs could ameliorate PFS in patients with platinum-resistant ROC with HR 0.83 (P = .067, Fig. 2). Significant heterogeneity existed among those 9 studies (I2 = 92.0%, P < .001). Compared with chemotherapy alone, the combined analysis showed that MTAs in chemotherapy used to treat ROC significantly ameliorated OS with HR 0.94 (P = .19, Figure S1, Supplemental Digital Content). Heterogeneity test showed that I2 was 0% and P was .87, so that we carried out a fixed-effects model. In addition, we found that MTAs in chemotherapy used to treat platinum-resistant ROC remarkably decreased ORR in comparison with treatment without MTAs (P = .012, Fig. 3). Heterogeneity testing showed I2 was 0%, and P was .72.

Figure 2.

Figure 2

Open in a new tab

Random-effect model of hazard ratio (95%CI) of PFS associated with chemotherapy with or without TAs in ROC patients. CI = confidence interval, PFS = progression-free survival, ROC = recurrent ovarian cancer, TAs = targeted agents.

Figure 3.

Figure 3

Open in a new tab

Fixed-effects model of relative ratio (95%CI) of ORR associated with chemotherapy with or without TAs in ROC patients. CI = confidence interval, ORR = objective response rate, ROC = recurrent ovarian cancer, TAs = targeted agents.

3.3. Toxicities

Due to multiple adverse events (AEs) of included targeted agents, we only analyzed the risk difference of any AEs which resulted in permanent discontinuation or fatal AEs between chemotherapy with MTAs and without MTAs. No significant heterogeneity of included trials was found so the fixed-effects model was used to analyze pooled results. Our results showed that combined use of MTAs with chemo notably raised the risk of any AEs resulting in discontinuation (P = .044, Fig. 4), but not influencing fatal AEs (P = .16, Figure S2, Supplemental Digital Content).

Figure 4.

Figure 4

Open in a new tab

Fixed-effects model of relative ratio (95%CI) of AEs leads to treatment discontinuation associated with chemotherapy with or without TAs in ROC patients. AEs = adverse events, CI = confidence interval, ROC = recurrent ovarian cancer, TAs = targeted agents.

3.4. Publication bias

The results of the funnel plot indicated the absence of remarkable asymmetry for PFS and OS analyzed by Begg or Egger test (P = .63 or P = .70) (Figure S3, Supplemental Digital Content and Figure 4, Supplemental Digital Content).

3.5. Discussion

OC is the leading cause of cancer-related mortality in gynecological malignancies worldwide.[30] At present, the first-line chemo for OC is on the basis of the combined use of platinum-derived cytotoxic agents and paclitaxel. Despite high response rate and median PFS, over 70% of these patients would finally suffer disease progression.[31] The emergency of resistance to platinum-resistant chemo mainly accounts for the deaths with recurrent OC. Currently, object response rates to frequently use of cytotoxic agents in platinum-refractory patients, such as pegylated liposomal doxorubicin,[32] gemcitabine,[33] topotecan,[34] and etoposide[35,36] are modest with a median overall survival of 9 to 12 months.[7,37] As combination cytotoxic agents for ROC did not show consistent benefits, no standard doublet combination therapy, except for bevacizumab, is recommended for ovarian cancer in this setting. Clearly, novel drugs or therapies will be used to increase platinum-resistant ROC patients’ survival. So far, a number of prospective trials have been conducted to extensively investigate the efficacy of several novel targeted agents, including aromatase inhibitors[38,39] and poly(ADP)-ribose polymerase inhibitors[40] for treating ROC in this setting. However, as far as we know, it is not clear whether MTAs in chemotherapy were effective in treating platinum-resistant ROC.

This study is the most comprehensive analysis, in which we clearly explore the effect of MTAs in chemotherapy for treating advanced platinum-resistant ROC. There were 3631 participates in 9 prospective clinical trials included in this study. Our combined results showed that MTAs in chemotherapy markedly increased ORR in patients with platinum-resistant ROC, but it had no effect on survival benefits, including PFS and OS. We also assess the toxicities associated related to the combination of MTAs with chemo, and the results indicated that MTAs with chemo markedly raised the risk of AEs, but it did not influence fatal AEs in platinum-resistant ROC. According to those results, we detect a significant ORR benefit and a tendency to improve PFS in patients with platinum-resistant ROC who were treated with MTAs, but the risk of developing severe toxicities was increased.

There are several strengths in this analysis. First, it is the first and most comprehensive study to determine the effect of MTAs with chemotherapy on the treatment of ROC. The quality of included trials was high according to the Jadad score. Additionally, all included trials are prospective RCTs. Finally, there are relatively limited heterogeneity and inconsistency of included trials and we also perform subgroup analysis to assess the potential heterogeneity.

However, several limitations of the present study are needed to be concerned. First, fatal AEs are not the primary endpoint and are extracted from clinical trials. The process of attribution of causality by investigators would be biased. Second, we analyzed various factors and signaling pathways related to MTAs, and it may increase the heterogeneity among included trials. Finally, only published studies were included in our study.

4. Conclusion

In conclusion, we explored the effect of the combination of MTAs with chemotherapy on the treatment of advanced platinum-resistant ROC patients. Our pooled results suggested that MTAs in chemotherapy significantly improved ORR in platinum-resistant ROC, but its benefit did not translate into survival benefits (PFS and OS). Further high-quality randomized trials are still needed to investigate the treatment for ROC.

Author contributions

Writing – original draft: Luting Liu, Wanchun Xiong.

Writing – review & editing: Luting Liu, Wanchun Xiong.

Supplementary Material

Supplemental Digital Content
medi-100-e26849-s001.doc (670.5KB, doc)

Supplementary Material

Supplemental Digital Content
medi-100-e26849-s002.docx (610.9KB, docx)

Supplementary Material

Supplemental Digital Content
medi-100-e26849-s003.docx (171.7KB, docx)

Supplementary Material

Supplemental Digital Content
medi-100-e26849-s004.docx (170.8KB, docx)

Footnotes

Abbreviations: AEs = adverse events, CI = confidence interval, HRs = hazard ratio, MTAs = molecular targeted agents, OC = ovarian carcinoma, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCTs = randomized controlled trials, ROC = recurrent ovarian cancer.

How to cite this article: Liu L, Xiong W. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: a systematic review and meta-analysis. Medicine. 2021;100:32(e26849).

The authors have no funding and conflicts of interest to disclose.

The datasets generated during and/or analyzed during the present study are available from the corresponding author on reasonable request.

Supplemental digital content is available for this article.

References

  • [1].Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. [DOI] [PubMed] [Google Scholar]
  • [2].Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012;120:612–8. [DOI] [PubMed] [Google Scholar]
  • [3].Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 2019. [DOI] [PubMed] [Google Scholar]
  • [4].Vergote I, Debruyne P, Kridelka F, et al. Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: a study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecol Oncol 2015;138:278–84. [DOI] [PubMed] [Google Scholar]
  • [5].Lee MX, Tan DS. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? J Gynecol Oncol 2018;29:e96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Tomao F, Marchetti C, Romito A, et al. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. Expert Opin Pharmacother 2017;18:1443–55. [DOI] [PubMed] [Google Scholar]
  • [7].Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol 2017;34:103. [DOI] [PubMed] [Google Scholar]
  • [8].Pan K, Gong J, Huynh K, Cristea M. Current systemic treatment landscape of advanced gynecologic malignancies. Target Oncol 2019. [DOI] [PubMed] [Google Scholar]
  • [9].Goff BA, Thompson T, Greer BE, Jacobs A, Storer B. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: a phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602). Am J Obstet Gynecol 2003;188:1556–62. discussion 1562-1554. [DOI] [PubMed] [Google Scholar]
  • [10].Aravantinos G, Bafaloukos D, Fountzilas G, et al. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 2003;14:1094–9. [DOI] [PubMed] [Google Scholar]
  • [11].Bamias A, Gibbs E, Khoon Lee C, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol 2017;28:1842–8. [DOI] [PubMed] [Google Scholar]
  • [12].Pawlowska A, Suszczyk D, Okla K, Barczynski B, Kotarski J, Wertel I. Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. Clin Exp Immunol 2019;195:334–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer: focus on rucaparib. Int J Womens Health 2017;9:913–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Ledermann JA. Front-line therapy of advanced ovarian cancer: new approaches. Ann Oncol 2017;28: suppl_8: viii46–50. [DOI] [PubMed] [Google Scholar]
  • [15].Lum C, Steer CB. Targeted therapies in the management of ovarian cancer: a focus on older patients. Drugs Aging 2017;34:821–31. [DOI] [PubMed] [Google Scholar]
  • [16].Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018;81:647–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015;16:87–97. [DOI] [PubMed] [Google Scholar]
  • [20].Moher D, Liberati A, Tetzlaff J, Altman DG. Group P.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol 2018;4:196–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Marth C, Vergote I, Scambia G, et al. ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer 2017;70:111–21. [DOI] [PubMed] [Google Scholar]
  • [23].Liu JF, Ray-Coquard I, Selle F, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol 2016;34:4345–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302–8. [DOI] [PubMed] [Google Scholar]
  • [25].Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15:799–808. [DOI] [PubMed] [Google Scholar]
  • [26].Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013;31:4400–6. [DOI] [PubMed] [Google Scholar]
  • [27].Kaye SB, Poole CJ, Danska-Bidzinska A, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 2013;24:145–52. [DOI] [PubMed] [Google Scholar]
  • [28].Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30:3841–7. [DOI] [PubMed] [Google Scholar]
  • [29].Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107–14. [DOI] [PubMed] [Google Scholar]
  • [30].Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs 2019;35:151–6. [DOI] [PubMed] [Google Scholar]
  • [31].Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther 2017;17:1147–58. [DOI] [PubMed] [Google Scholar]
  • [32].Shoji T, Takatori E, Omi H, et al. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer Chemother Pharmacol 2017;80:355–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Niu J, Kundranda MN, Markman M, Farley J. Platinum-gemcitabine-avastin (PGA) for platinum-resistant/refractory ovarian cancer. Eur J Gynaecol Oncol 2017;38:40–4. [PubMed] [Google Scholar]
  • [34].Poveda A, Del Campo JM, Ray-Coquard I, et al. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Ann Oncol 2017;28:1280–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].Bozkaya Y, Dogan M, Umut Erdem G, et al. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer. J Obstet Gynaecol 2017;37:649–54. [DOI] [PubMed] [Google Scholar]
  • [36].Kucukoner M, Isikdogan A, Yaman S, et al. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev 2012;13:3973–6. [DOI] [PubMed] [Google Scholar]
  • [37].Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol 2017;28: suppl_8: viii51–6. [DOI] [PubMed] [Google Scholar]
  • [38].Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol 2017;145:393–406. [DOI] [PubMed] [Google Scholar]
  • [39].Napoletano C, Ruscito I, Bellati F, et al. Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets. J Clin Med 2019;8(3.): [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Al Hadidi S, Aburahma A, Badami S, Upadhaya S. PARP (poly(ADP-ribose) polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: a meta-analysis of randomized controlled trials. Oncol Res Treat 2018;41:226–35. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Digital Content
medi-100-e26849-s001.doc (670.5KB, doc)
Supplemental Digital Content
medi-100-e26849-s002.docx (610.9KB, docx)
Supplemental Digital Content
medi-100-e26849-s003.docx (171.7KB, docx)
Supplemental Digital Content
medi-100-e26849-s004.docx (170.8KB, docx)

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES